We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Dermavant

News List

Dermavant raises $200m to support tapinarof launch pharmaceutical-technology
June 10, 2021
Dermavant Sciences has signed a $160m revenue interest purchase and sale agreement for tapinarof with Marathon Asset Management, NovaQuest Capital Management and a third unnamed institutional investor in the US.
Dermavant sells Tapinarof commercial rights in Japan pharmaceutical-technology
January 19, 2020
Dermavant Sciences, a subsidiary of Roivant Sciences, has signed an exclusive agreement to sell the development and commercial rights of tapinarof in Japan.
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 16, 2018
Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) which has been evaluated as a topical therapy in multiple Phase I and Phase II studies involving over 800 human subjects.
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 13, 2018
GlaxoSmithKline has sold rights to an experimental therapy with potential in psoriasis and dermatitis to Dermavant in a deal worth $330 million.